GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy

GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy

Glioblastoma (GBM) is a common primary brain tumor with poor clinical prognosis. Although CAR-T therapy has been trialed for treatment of GBM, the outcomes are sub-optimal possibly due to exhaustion of T cells and life-threatening neurotoxicity. To address these issues, a combined therapeutic strate...

Full description

Bibliographic Details
Main Authors: Guangji Zhang, Yu Zhao, Zhongfeng Liu, Weihua Liu, Huantong Wu, Xuan Wang, Zhiguo Chen
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Translational Oncology
Subjects:
Glioblastoma
GD2
CAR-T
PD-1
Tumor microenvironment
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523323000499

Internet

http://www.sciencedirect.com/science/article/pii/S1936523323000499

Similar Items